At Pharmaceuticals, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.
With our innovative products, we seek to achieve therapeutic benefit for patients, while at the same time satisfying the growing requirements of physicians and health insurers.
Our drug discovery researchers concentrate on the areas of cardiology, oncology, hematology, ophthalmology and gynecology. They are looking for either small molecules or biologics that could serve as new active ingredients. We continue to develop products even after they have been approved in order to optimize patient benefit through new delivery forms or a broader range of indications. Our recently launched active ingredients, such as rivaroxaban, aflibercept, regorafenib, radium-223 dichloride and riociguat, are intended to contribute to sales growth in the medium term.
In the radiology area, we are concentrating on the development of IT applications, contrast agents and injection systems for low-radiation computed tomography (CT) and high-field magnetic resonance imaging (MRI) to enable us to offer integrated solutions.
Our principal research centers are located in Berlin, Wuppertal and Cologne, Germany; San Francisco and Berkeley, United States; Turku, Finland; and Oslo, Norway.
Complementing our own research capacities are collaborations and strategic alliances with external partners in academia and industry. We are convinced that strong partnerships stimulate innovation and facilitate the joint development of new approaches that benefit patients. In recent years we have developed a variety of successful collaboration models, including research and development cooperations, license agreements, co-marketing arrangements, regional collaborations and acquisitions.
We also operate our own science and innovation centers. Research partnerships in America and Asia are coordinated through our science hubs in San Francisco and Cambridge, United States; Beijing, China; Singapore; and Osaka, Japan. Our CoLaborator™ concept provides life science startups with suitable lab and office infrastructure in Berlin, Germany, and San Francisco, United States, in close proximity to Bayer’s research facilities. In addition, Bayer has initiated a variety of open innovation programs, such as Grants4Targets™, Grants4Indications™, PartnerYourAntibodies™ and Grants4Apps™.
Bayer supports leading organizations in the fight against neglected tropical diseases by providing active ingredients free of charge. The World Health Organization (WHO) uses our medicines to treat Chagas disease, which is widespread in Latin America, and African sleeping sickness. In partnership with the Drugs for Neglected Diseases initiative (DNDi), we are examining whether the active ingredient emodepside (originally from the Japanese company Astellas) could be used to treat people with river blindness. Bayer is also currently developing a new formulation of the active ingredient nifurtimox in order to test a more individualized dosage. This should simplify the treatment of children, who are especially vulnerable to Chagas disease.
As the market leader in hormonal contraceptives, we have for nearly 50 years supported the family planning programs of a global network of governmental and nongovernmental organizations (NGOs), including the Bill & Melinda Gates Foundation. Through innovative partnerships, Bayer is thus helping to ensure that women in developing countries have long-term access to hormonal contraceptives.